fletikumab Is a monoclonal antibody and has no relationship to the MOA of a nucleoside analog reverse transcriptase inhibitor. Looking at a safety and tolerability trial that lead to abandoning fletikumab for psoriasis in order to glean some kind of insight into Prurisol (Abacavir) is a waste of time.
Market Data 
Markets 
AI
